The method for the synthesis of ethyl 4-[3-(ethoxycarbonyl)-1-phenyl-1H-pyrazol-4-yl]-2-oxo/thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylates was developed, and the bioactivity of the obtained compounds against infectious agents was predicted. Docking studies of the synthesised compounds were performed on pteridine reductase 1 (PTR1) of Leishmania, dihydrofolate reductase–thymidylate synthase of Trypanosoma cruzi, and human dihydrofolate reductase. The results demonstrated that the investigated compounds exhibit high affinity for these enzymes. Moderate selectivity relative to human DHFR was also observed. In addition, the predicted drug-likeness, ADME-Tox parameters, and toxicity profiles suggest the potential of the synthesised compounds for further pharmacological development.

Rhodanines are recognized as privileged heterocycles in medicinal chemistry. The main achievements include the development of drug-like molecules with numerous biological activities as well as approved drugs. The Furan nucleus is considered one of the promising heterocyclic cores in medicinal chemistry that showed numerous ranges of activity. The combination of several heterocycles in a one molecule commonly provides much more interest in the enhanced activity profile of its analogs than their parent separate constituents. Such conjugates are promising objects for modern medicinal chemistry. In this review paper recent advances in the synthesis and biological activities rhodanine-furan conjugates which its application in the different field of drug discovery.